Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 13;21:11. doi: 10.1186/s40644-021-00381-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — Therapeutic monitoring of ¹⁸F-FDG-PET in 71-years old male with advanced pulmonary adenocarcinoma who received pembrolizumab monotherapy as 1st line treatment. a ¹⁸F-FDG-PET/CT before pembrolizumab initiation shows primary site in the right upper lobe and hilum-mediastinal lymphadenopathy. Mediastinal lymphadenopathy before trachea revealed increased accumulation of ¹⁸F-FDG (black and white arrows) with SUV_max of 15, corresponding to that on CT scan (red arrow). b At 1 month after pmebrolizumab treatment, uptake of ¹⁸F-FDG on PET was obviously decreased with SUV_max of 3, but the morphological size of its lymphadenopathy was not changing (red arrow). c At 3 months after its treatment, there was no accumulation of ¹⁸F-FDG in primary site and lymphadenopathy (black and white arrows) with morphological shrinkage on CT scan (red arrow)